RxDoctor Payments Data

Basil Dudar, MD

Cardiovascular Disease · St Clair Shores, MINPI 1407804958

Payments from drug & device makers

$2,807in general payments, 2019–2025

Across 43 payments — averaging $65.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Amgen$275
  • Boston Scientific$135
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$75
  • Cordis US CORP.$52
  • E.r. Squibb & Sons, L.L.C.$45
  • plus $274 from 10 others

What the payments were for

  • Travel & lodging$1,60957%
  • Food & beverage$1,16341%
  • Education$361%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,807 in reported general payments places this provider in the 45th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$238,483
Medicare patients
676
Services billed
2,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban471$525,954
XareltoRivaroxaban117$162,421
Repatha SureclickEvolocumab103$65,093
EntrestoSacubitril/Valsartan25$47,834
Metoprolol Succinate611$11,597
BrilintaTicagrelor17$10,709
FarxigaDapagliflozin Propanediol12$10,616
Praluent PenAlirocumab18$9,722
Rosuvastatin Calcium427$8,004
Repatha SyringeEvolocumab12$7,222
Ranolazine ErRanolazine39$5,537
Diltiazem 24hr Er (Cd)Diltiazem Hcl115$5,373
Atorvastatin Calcium325$5,092
Carvedilol299$3,900
Losartan Potassium302$3,652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$42$162,421117 claims
NovartisEntresto$44$47,83425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in St Clair Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →